



Inviragen Merger Profiled in Inc. Magazine

Fort Collins, Colorado

7 May 2010

Inviragen's recent merger with SingVax is profiled this month in Inc. magazine, a national publication that delivers advice, tools, and services to help business owners and CEOs start, run, and grow their businesses more successfully.

In September 2009, Inviragen, a U.S.-based vaccine company, and SingVax, a Singapore-based vaccine company, merged to create a company that is developing vaccines for infectious diseases prevalent in emerging economies. Concurrent with the merger, the combined company raised \$15 million in a Series A equity investment from a syndicate of international venture capital investors.

The complexities of an international merger with multiple investors, enormous physical distance, and the difficulties meshing leadership and prioritizing multiple resource needs intrigued one of the writers for Inc. and a feature story resulted. For the full article, please see <http://www.inc.com/magazine/20100501/case-study-attempting-a-global-merger.html>.

"Post-merger, we have combined our operations and are capitalizing on the synergy created," noted Dr. Joseph Santangelo, Inviragen's Chief Operating Officer. "Our integrated international R&D capabilities position us well to continue to translate needed vaccines from the bench to the clinic."

"We are pleased that now, six months after the official merger, Inviragen is rapidly moving ahead," commented Dr. Dan Stinchcomb, Inviragen's Chief Executive Officer. "We have three vaccines poised to begin human clinical trials. Our lead vaccine, designed to protect against dengue fever, will begin clinical trials this quarter."

About Inviragen

Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever, a disease that threatens 3.6 billion people across the globe. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical research stages include a low-cost human papilloma virus vaccine, a chikungunya vaccine, and vaccines to protect against new forms of influenza for global health markets. Inviragen has offices and laboratories in Fort Collins, Colorado, Madison, Wisconsin and Singapore. Please see www.inviragen.com for more details.